Zafrens has developed an ultrahigh-throughput single cell platform to isolate, image, run assays
Mitsui Chemicals announced that it has invested in Zafrens, a company supporting drug discovery through high-throughput single-cell analysis, via 321FORCE Global Innovation Fund.
Zafrens has developed an ultrahigh-throughput single cell platform to isolate, image, run assays on and sequence 50,000–200,000 cells per experiment. This platform makes it possible to understand cell behavior and decode how a cell’s molecular profile (DNA, RNA, protein) translates to its function at scale. Further, the platform’s ability to seamlessly span different therapeutic modalities allows it to rapidly generate deep insights.
Subscribe to our newsletter & stay updated.
